Financings in Brief: Vidamed
This article was originally published in The Gray Sheet
Vidamed: Files with the Securities and Exchange Commission for the issuance of up to 950,000 shares of common stock that will enable the firm to complete a financing arrangement with Dutch merchant bank MeesPierson worth up to $10 mil. The funds are tabbed for working capital to launch the Menlo Park, California firm's TUNA transurethral needle ablation system for treatment of benign prostatic hyperplasia. The system was cleared via 510(k) in October 1996 ("The Gray Sheet" Oct. 14, 1996, I&W-4)...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.